source
- FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefitThe U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
- Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cutsAt the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…